Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
  • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Definitions

• the invention generally relates to a method for the prevention, alleviation and/or treatment of hamartomatous diseases using compounds that modulate endoplasmic reticulum (ER) stress. More specifically, the invention relates to the prevention, alleviation, and/or treatment of tuberous sclerosis using chemical chaperones or agents that promote ER stress. The invention further relates to methods for screening compounds that modulate ER stress using cells containing a mutation in a tuberous sclerosis complex (TSC) gene.
• TSC tuberous sclerosis complex
• Tuberous sclerosis also called tuberous sclerosis complex (TSC)
• TSC tuberous sclerosis complex
• the tumors may be found in the brains (e.g., cortical tubers, subependymal nodules, and giant-cell astrocytomas) and on other vital organs such as the kidneys (e.g., angiomyolipomas), heart (e.g., cardiac rhabdomyomas), eyes (e.g., phakomas), lungs, liver, pancreas, and skin (e.g., hypomelanic macules, facial angiofibromas, forehead plaques, shagreen patches, ungual and subungual fibromas, molluscum fibrosum, café au lait spots, and poliosis).
• the kidneys e.g., angiomyolipomas
• heart e.g., cardiac rhabdomyomas
• eyes e.g., phakomas
• lungs liver,
• Tuberous sclerosis The tumors in tuberous sclerosis are rarely malignant however.
• the disease commonly affects the central nervous system leading to neurological problems such as seizures, mental retardation, and behavior problems.
• Bone cysts, rectal polyps, gum fibromas, and dental pits are also seen in patients with tuberous sclerosis (Kwiatkowski, “Tuberous sclerosis: from Tubers to mTOR” Annals of Human Genetics 67:87-96, 2003; Lendvay et al. “The Tuberous Sclerosis Complex and Its Highly Variable Manifestations” J. Urology 169:1635-42, 2003; each of which is incorporated herein by reference).
• tuberous sclerosis may be present at birth, the signs of the disorder may be subtle and full symptoms may take some time to develop. As a result, tuberous sclerosis is frequently unrecognized and/or misdiagnosed for years.
• Tuberous sclerosis affects an estimated 25,000 to 40,000 individuals in the United States and about 1 to 2 million individuals worldwide. Tuberous sclerosis is seen in approximately 1 out of 6,000 newborns. The disorder has been found in all races and ethnic groups, and in both genders. No racial or sex predilections have been observed. The disorder was once known as epiloia or Bourneville's disease.
• tuberous sclerosis Most cases of tuberous sclerosis occur as spontaneous mutations. However, the disease may be inherited from a parent with tuberous sclerosis. Individuals who inherit tuberous sclerosis may not have the same symptoms as their parent with the disorder.
• TSC1 and TSC2 The genes causing tuberous sclerosis have been identified and named TSC1 and TSC2 (van S strengenhorst et al. “Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34” Science 277:805-8, Aug. 8, 1997; European Chromosome Tuberous Sclerosis Consortium, “Identification and Characterization of the Tuberous Sclerosis Gene on Chromosome 16 ” Cell 75:1305-1315, 1993; each of which is incorporated herein by reference). Only one of the genes needs to be affected for tuberous sclerosis to be present.
• the TSC1 gene was discovered in 1991 and is found on chromosome 9, specifically 9q34. It produces a protein call hamartin.
• the second gene, TSC2 was discovered in 1993. It is found on chromosome 16, specifically 16p13, and produces the protein tuberin.
• the invention includes a method for the prevention, alleviation, and/or treatment of hamartomatous disease, particularly tuberous sclerosis, using agents to decrease ER stress such as chemical chaperones.
• the present invention stems from the recognition that tuberous sclerosis is associated with endoplasmic reticulum (ER) stress. Mutations in TSC1 and TSC2, the genes identified as causing tuberous sclerosis, result in uncontrolled activity of the mammalian target of rapamycin (mTOR) signaling pathway that results in severe ER stress. Tumors derived from a mouse model of tuberous sclerosis were found to exhibit high levels of ER stress. Furthermore, ER stress was also evident in human tumors of patients with tuberous sclerosis. Endoplasmic reticulum stress associated with tuberous sclerosis was reversed by the treatment of cells with agents that reduce ER stress (e.g., chemical chaperones), thereby providing a new treatment option for tuberous sclerosis patients.
• agents that reduce ER stress e.g.
• the invention further includes a method for the prevention, alleviation, and/or treatment of hamartomatous disease, particularly tuberous sclerosis by administration of agents to induce ER stress. It has been found that the TSC-deficient cells are highly sensitive to ER stress and can be selectively killed by treatment with low doses of ER-stress inducing agents that do not affect normal tissues at comparable doses. These results have been confirmed in animal studies in which administration of a low dose of an ER stress inducing agent was demonstrated to increase cell death in kidney and liver tumors in TSC-deficient mice. No increase in apoptosis was observed in normal tissue in response to the agent.
• the invention also includes a method for promoting apoptosis in TSC-deficient cells comprising administration of a dose of an ER-stress inducing agent at a level which the ER stress inducing agent does not induce significant apoptosis in normal (e.g., wild-type) or non-tumor cells or tissues.
• Tumors associated with tuberous sclerosis can be treated by administering to a subject an agent that increases the ER stress response (e.g., thapsigargin, tunicamycin, azetidine-2 carboxylic acid (Azc, a purine analog)) to eliminate TSC-deficient cells.
• an agent that increases the ER stress response e.g., thapsigargin, tunicamycin, azetidine-2 carboxylic acid (Azc, a purine analog
• TSC1- and TSC2-deficient cells are used as a cell model of spontaneous ER stress. These cells can be used in a system to investigate ER stress in cells or to identify new ER stress modulators. For examples, these cells can be used in screening methods, including high throughput screening methods, to identify agents that modulate the ER stress response.
• test compounds are contacted, preferably independently, with TSC1- and/or TSC2-deficient cells, and analyzed for a change in the levels of at least one ER stress marker as compared to control cells or samples.
• ER stress markers include spliced forms of Xbox binding protein-1 (XBP-1); phosphorylated protein kinase-like ER kinase (PERK), eukaryotic initiation factor 2 ⁇ (eIF2 ⁇ ), and inositol requiring enzyme (IRE-1); increased mRNA and/or protein expression of GRP78/BIP and C/EPB homologous protein (CHOP); and c-Jun N-terminal kinase (JNK) activation.
• Analysis of the level of at least one marker in response to a test compound is used to identify agents that modulate (i.e., increase or decrease) ER stress. The identified agents are also part of the present invention.
• test compounds include, but are not limited to, small molecules, polynucleotides, proteins, and peptides.
• the test compounds are small molecules.
• the test compounds are polynucleotides such as siRNAs.
• the identified agents may be used in pharmaceutical compositions to treat any disease or condition associated with ER stress (e.g., tuberous sclerosis, hypercholesterolemia, hyperlipidemia, type II diabetes, obesity, etc.)
• ER stress results from a disequilibrium between ER load and folding capacity, and can be triggered by any of a number of factors including hypoxia, hypoglycemia, toxins, and genetic predisposition.
• the agents are administered to a subject in therapeutically effective amounts to prevent, alleviate, and/or treat a disease or condition associated with ER stress.
• Agents useful in the treatment of tuberous sclerosis include small molecules, proteins, nucleic acids, and any other chemical compounds known to reduce or prevent ER stress. These agents may act in any manner that reduces or prevents ER stress such as reducing the production of mutant or misfolded proteins, increasing the expression of ER chaperones, increasing the stability of proteins, boosting the processing capacity of the ER, etc.
• Particularly useful agents include chemical chaperones such as 4-phenyl butyrate (PBA), tauroursodeoxycholic acid (TUDCA), ursodeoxycholic acid (UDCA), trimethylamine N-oxide (TMAO), glycerol, D 2 O, dimethylsufloxide, glycine betaine, methyl amines, and glycerophosphocholine.
• PBA 4-phenyl butyrate
• TDCA tauroursodeoxycholic acid
• UDCA ursodeoxycholic acid
• TMAO trimethylamine N-oxide
• glycerol D 2 O
• dimethylsufloxide glycine betaine
• methyl amines glycerophosphocholine
• both PBA and TUDCA have been shown to regulate ER stress in animals as measured by the reduced phosphorylation of PERK, reduced activation of JNK, and reduced phosphorylation of IRE-1 ⁇ , as determined by western blot after treatment of the animal with the compound.
• the agent or a pharmaceutical composition comprising the agent is administered to a subject (e.g., human, dog, cat, mammal, animal) in doses effective to reduce ER stress, and thereby treat tuberous sclerosis and other hamartomatous disease.
• the invention also provides methods of alleviating, treating, and/or preventing tuberous sclerosis by administering agents that reduce ER stress.
• the agents may be administered in any manner known in the drug delivery art although preferably the agent is delivered orally or parenterally. Dose ranges for these agents depend on the agent being delivered as well as other factors but will typically range from about 1 mg/kg/day to about 10 g/kg/clay, but may be dosed at other levels.
• agents, pharmaceutical compositions, and treatment methods may also be used in the treatment of other hamartomatous diseases such as pulmonary hamartoma, von Meyenburg complex, proteus syndrome, Birt-Hogg-Dube syndrome, multiple hamartoma syndrome, neurofibromatosis type 1, Peutz-Jeghers syndrome, Riley-Smith syndrome, and angiomyolipoma.
• hamartomatous diseases such as pulmonary hamartoma, von Meyenburg complex, proteus syndrome, Birt-Hogg-Dube syndrome, multiple hamartoma syndrome, neurofibromatosis type 1, Peutz-Jeghers syndrome, Riley-Smith syndrome, and angiomyolipoma.
• the effectiveness of the treatment using ER stress modulators may be monitored by determining the levels of at least one ER stress marker in the subject being treated.
• reduced indicators of ER stress indicate the treatment is working.
• increased indicators of ER stress, cell death, or apoptosis indicate that the treatment is working.
• the agent used to treat tuberous sclerosis is 4-phenyl butyric acid (PBA).
• PBA has been shown to regulate ER stress.
• Phenyl butyric acid (PBA), or a derivative or salt thereof is administered to a subject in order to reduce ER stress and is particularly useful in the treatment of tuberous sclerosis.
• the administration of PBA results in a reduction in the signs and symptoms of tuberous sclerosis.
• PBA prevents or slows the growth of tumors associated with tuberous sclerosis. Increased ER stress in TSC2 ⁇ / ⁇ cells is inhibited by treatment with PBA.
• PBA or a pharmaceutical composition thereof, is administered in doses ranging from about 10 mg/kg/day to about 2 g/kg/day, preferably from about 100 mg/kg/day to about 1 g/kg/day, more preferably from about 500 mg/kg/day to about 1 g/kg/day.
• tauroursodeoxycholic acid a bile acid
• TDCA tauroursodeoxycholic acid
• TUDCA has been shown to regulate ER stress.
• the invention provides the administration of tauroursodeoxycholic acid (TUDCA) or a salt or derivative thereof to a subject in order to reduce ER stress.
• TUDCA, or a pharmaceutical composition thereof is administered in doses ranging from about 10 mg/kg/day to about 2 g/kg/day, preferably from about 100 mg/kg/day to about 1 g/kg/day, more preferably from about 250 mg/kg/day to about 750 mg/kg/day.
• TMAO is the agent used to reduce ER stress.
• the invention provides the administration of TMAO or a salt or derivative thereof to a subject in order to reduce ER stress.
• TMAO, or a pharmaceutical compositions thereof is administered in doses ranging from 10 mg/kg/day to 5 g/kg/day, preferably from 100 mg/kg/day to 1 g/kg/day, more preferably from 250 mg/kg/day to 750 mg/kg/day.
• compositions and medicaments including agents that modulate ER stress (e.g., PBA, TUDCA, UDCA, TMAO, thapsigargin, tunicamycin, azetidine-2 carboxylic acid (Azc)) and pharmaceutically acceptable excipients are also provided.
• the pharmaceutical compositions may be formulated for oral, parenteral, or transdermal delivery.
• the ER stress reducing agent may also be combined with other pharmaceutical agents.
• the agents may be combined in the same pharmaceutical composition or may be kept separate (i.e., in two separate formulations) and provided together in a kit.
• the kit may also include instructions for the physician and/or patient, syringes, needles, box, bottles, vials, etc.
• the invention provides a method of screening for agents that reduce ER stress and that are useful in the treatment of tuberous sclerosis or other hamartomatous diseases.
• Agents to be screened are contacted with at least one TSC-deficient cell and preferably at least one control cell.
• TSC2 ⁇ / ⁇ cells are used in screening for agents that modulate ER stress.
• TSC1 ⁇ / ⁇ cells are used in screening for agents that modulate ER stress.
• heterozygous TSC-deficient cells are used in screening for agents that modulate ER stress.
• Cells may be primary cells obtained from an animal or patient, or tissue culture cells modified to include mutations and/or deletions in at least one of the TSC genes.
• Cells particularly useful in the inventive screen include mammalian cells, particularly human cells.
• the levels of ER stress markers are compared to levels of the same stress marker in control cells or tissues to identify agents that reduce ER stress.
• the selection and use of control samples is well understood by those skilled in the art.
• markers of ER stress include spliced forms of XBP-1, phosphorylated PERK, eIF2 ⁇ , and IRE-1 ⁇ ; increased mRNA and/or protein levels of GRP78/BIP and CHOP; reduced insulin signaling; and JNK activation.
• Agents that reduce at least one marker of ER stress as compared to an untreated control cell are identified as agents that reduce ER stress.
• a decrease in the levels of an ER stress marker is indicative of an agent that can be useful in treating diseases associated with ER stress, such as tuberous sclerosis and other hamartomatous diseases.
• a similar screening method can be used for agents that cause increased ER stress.
• cells may be exposed to conditions or compounds that induce ER stress, including, but not limited to, glucose starvation in TSC-deficient cells, or treatment with ER stress inducing agents of normal cells, prior to, simultaneous with, and/or after exposure to test agents.
• Agents identified using the inventive method are part of the invention. These agents may be further tested for use in pharmaceutical compositions and medicaments.
• the invention further includes a kit for screening agents to modulate ER stress.
• the invention provides a method of diagnosing tuberous sclerosis, monitoring the progression of the disease, or monitoring treatment of the disease by analyzing levels of ER stress markers.
• Markers indicative of ER stress include, but are not limited to, spliced forms of XBP-1; phosphorylated PERK, eIF2 ⁇ and IRE-1 ⁇ ; increased mRNA and/or protein levels of GRP78/BIP and/or CHOP; decreased insulin signaling; and JNK activation.
• the amount of marker present in a test sample suspected of undergoing ER stress e.g., tumor tissue from an individual having a TSC-deficiency
• normal tissue preferably from a site close to or adjacent to the test sample to be analyzed.
• Any cellular marker known to be indicative of ER stress may also be used to identify ER stress.
• the levels of these markers may be measured by any method known in the art including western blot, enzyme-linked immunosorbent assay (ELISA), northern blot, immunoassay, immunohistochemistry, rtPCR, especially quantitative rtPCR, PCR in situ, or enzyme assay.
• the specific method of detection of an altered level of at least one ER stress marker is not a limitation of the invention. In the diagnostic method, an increase in the level of an ER stress markers indicates that the subject is at risk for tuberous sclerosis or other harmatomatous disease.
• a reduction in ER stress markers indicates a reduction in the progression of the disease or a success in treating the disease with ER stress reducers.
• ER stress inducers are used to induce cell death in tuberous sclerosis-associated tumors, an increase in ER stress markers indicates a successful treatment, however a more likely endpoint for monitoring would be an increase in cell death (e.g., apoptosis).
• Alleviate The term alleviate, as used herein, is understood as to make a condition, such as tuberous sclerosis or other hamartomatous disease, more bearable, and/or to partially remove or correct at least one symptom and/or hallmark of the disease. Alleviation of a disease or symptoms thereof does not require curing the disease or completely eliminating any or all of the symptoms of the disease. More than one dose of an agent that modulates ER stress may be required for the alleviation of disease.
• Animal refers to humans as well as non-human animals, including, for example, mammals, birds, reptiles, amphibians, and fish.
• the non-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a primate, or a pig).
• the animal is a human.
• Cell includes any cell.
• the cell is prokaryotic.
• the cell is eukaryotic.
• a cell of the invention is a bacterial cell.
• a cell of the invention is a fungal cell, such as a yeast cell.
• a cell of the invention is a vertebrate cell, e.g., an avian or mammalian cell.
• a cell of the invention is a human cell.
• the cell is derived for a tumor (e.g., angiomyolipomas, brain tumors, cortical tumors, subependymal nodules, giant-cell astrocytomas, rhabdomyomas, phakomas, facial angiofibromas, ungual or subungual fibromas, molluscum fibrosum, etc.) associated with tuberous sclerosis.
• a tumor e.g., angiomyolipomas, brain tumors, cortical tumors, subependymal nodules, giant-cell astrocytomas, rhabdomyomas, phakomas, facial angiofibromas, ungual or subungual fibromas, molluscum fibrosum, etc.
• TSC-deficient e.g. TSC1 ⁇ / ⁇ , TSC1+/ ⁇ , TSC2 ⁇ / ⁇ , or TSC2+/ ⁇ .
• “Chemical chaperone” As used herein, a “chemical chaperone” is one of a chemically diverse class of compounds known to increase ER capacity, stabilize protein conformation against denaturation, and/or to facilitate protein folding or re-folding, thereby preserving and/or maintaining protein structure and function (Welch et al. Cell Stress Chaperones 1:109-115, 1996; incorporated herein by reference).
• the “chemical chaperone” is a small molecule or low molecular weight compound.
• the “chemical chaperone” is not a protein.
• “chemical chaperones” include, but are not limited to glycerol, deuterated water (D 2 O), dimethylsulfoxide (DMSO), trimethylamine N-oxide (TMAO), glycine betaine (betaine), glycerolphosphocholine (GPC) (Burg et al. Am. J. Physiol . ( Renal Physiol. 43):F762-F765, 1998; incorporated herein by reference), 4-phenyl butyrate or 4-phenyl butyric acid (PBA), methylamines, ursodeoxycholic acid (UDCA), and tauroursodeoxycholic acid (TUDCA). Chemical chaperones may be used to influence the protein folding in a cell.
• D 2 O deuterated water
• DMSO dimethylsulfoxide
• TMAO trimethylamine N-oxide
• TMAO glycine betaine
• GPC glycerolphosphocholine
• PBA 4-phenyl butyrate or 4-
• Chemical chaperones also find use in the reduction of ER stress and are useful in the treatment of obesity, type II diabetes, insulin resistance, and hyperglycemia (See, e.g., ⁇ zcan et al., Science 313:1137-40, 2006; PCT/US2005/032840 and PCT/US2005/032841, all three of which are incorporated herein by reference).
• Preferred chemical chaperones of the instant invention include compounds that decrease the level of ER stress as determined by a decrease in the level of at least one ER stress marker in cells as compared to the level of the marker in cells prior to exposure to the chemical chaperone.
• ER stress can be due to stress (e.g., hypoxia, hypoglycemia), chemical stimulation, or the presence of a mutation in the cell that results in ER stress.
• the “effective amount” of an active agent refers to the amount of the active agent necessary to elicit the desired biological response.
• the effective amount of an agent that modulates ER stress may vary depending on such factors as the desired biological endpoint, the agent being delivered, the disease being treated, the subject being treated, route of administration etc.
• An effective amount is not a specific dose or dosage regimen, but instead it is the amount determined by a qualified individual, such as a physician, to be an appropriate dose for an individual for the prevention, alleviation, and/or treatment of a disease associated with ER stress, particularly tuberous sclerosis.
• the effective amount of agent used to treat tuberous sclerosis is the amount that results in a reduction in the signs and symptoms of the disease (e.g., tumor growth, number of tumors, severity of seizures, number of seizures, progression of renal disease, etc.).
• the effective amount of the ER stress modulator reduces the levels of at least one ER stress marker.
• the levels of at least two, three, four, or more ER stress markers are reduced.
• the ER stress marker may be reduced by approximately 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 100%.
• Endoplasmic reticulum (ER) stress inducing agent refers to any of a number of chemically diverse compounds that increase the level of stress in the ER as determined by an increase in at least one ER stress marker in cells as compared to the level of the ER stress marker prior to exposure to the ER stress inducing agent.
• Cells include those already undergoing ER stress.
• ER stress inducing agents include, but not limited to, thapsigargin, tunicamycin, azetidine-2 carboxylic acid (Azc, a purine analog).
• Endoplasmic reticulum (ER) stress markers refers to the hallmarks of ER stress, such as those observed in TSC-deficient cells. Markers can be proteins that are modified (e.g., phosphorylated or dephosphorylated) or translocated in response to ER stress (e.g., translocation of spliced forms of XPB-1 to the nucleus). mRNA and/or protein levels, or mRNA splicing may also be altered in response to ER stress resulting in the production of different amounts or isoforms of proteins.
• ER stress markers but are not limited to, an increased amount of spliced XBP-1 as compared to unspliced XBP-1-; phosphorylated PERK, eIF2 ⁇ , and IRE-1 ⁇ , increased expression of GRP78/BIP and CHOP mRNA and protein; decreased insulin signaling; increased expression of mRNA and protein of components of the UPR; and JNK activation.
• the level of an ER stress markers in a cell suspected of undergoing ER stress is compared to level of the same ER stress marker in control cells not undergoing ER stress (e.g., cells contacted with a test agent are compared to cells not exposed to a test agent; tumor cells are compared to normal cells, preferably from the same tissue). Each ER stress marker can be assessed individually.
• Endoplasmic reticulum (ER) stress modulating agent refers to any of a number of chemically diverse compounds that increase or decrease the level of stress in the ER as determined by a change in the level of at least one ER stress marker in normal cells or cells undergoing ER stress due to mutation and/or chemical stimulation.
• ER stress modulating agents include chaperones, especially chemical chaperones, that reduce the level of ER stress.
• ER stress modulating agents include agents that increase ER stress including, but not limited to, thapsigargin, tunicamycin, azetidine-2 carboxylic acid (Azc, a purine analog).
• peptide or “protein”: According to the present invention, a “peptide” or “protein” comprises a string of at least three amino acids linked together by peptide bonds.
• protein and “peptide” may be used interchangeably.
• Inventive peptides preferably contain only natural amino acids, although non-natural amino acids (i.e., compounds that do not occur in nature but that can be incorporated into a polypeptide chain) and/or amino acid analogs as are known in the art may alternatively be employed.
• one or more of the amino acids in an inventive peptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, etc.
• a chemical entity such as a carbohydrate group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, etc.
• the modifications of the peptide lead to a more stable peptide (e.g., greater half-life in vivo). These modifications may include cyclization of the peptide, the incorporation of D-amino acids, etc. None of the modifications should substantially interfere with the desired biological activity of the peptide.
• Polynucleotide or “oligonucleotide” refers to a polymer of nucleotides.
• the polymer may include natural nucleosides (i.e., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine), nucleoside analogs (e.g., 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C 5 -iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 7-deazaadenosine, 7-deazaguanosine, 8-oxo
• Prevent is understood as to keep at least one symptom and/or hallmark of a disease, particularly tuberous sclerosis, from happening or existing in a subject. Prevention can be understood in limiting spreading or exacerbation of symptoms and/or hallmarks of the disease in a subject already diagnosed with tuberous sclerosis or other hamartomatous disease. More than one dose of an agent that modulates ER stress may be required for the prevention of disease.
• ER stress inducing agents are often toxic, and apoptosis occurs naturally in cells and tissues. Therefore, is it possible that ER stress inducing agents can be specific for inducing apoptosis in TSC-deficient cells or cells undergoing ER stress so long as significant apoptosis is not observed in normal control or adjacent, non-tumor cells or tissue.
• Small molecule refers to organic compounds, whether naturally-occurring or artificially created (e.g., via chemical synthesis) that have relatively low molecular weight (e.g., less than about 7500, less than about 5000, less than about 1000 molecular weight or less than about 500 molecular weight) and that are not proteins, polypeptides, or nucleic acids. Typically, small molecules have a molecular weight of less than about 1500 g/mol. Also, small molecules typically have multiple carbon-carbon bonds. Small molecules can be used as test compounds in the inventive screening method. In one embodiment, small molecules do not exclusively comprise peptide (amide) bonds. In another embodiment, small molecules are not oligomeric.
• Exemplary small molecule compounds include, but are not limited to, peptidomimetics, small organic molecules (e.g., Cane et al. 1998 . Science 282:63; incorporated herein by reference), and natural product extract libraries.
• the compounds are small, organic non-peptidic compounds.
• a small molecule is not biosynthetic.
• a small molecule is preferably not itself the product of transcription or translation.
• Spliced forms of XBP-1 refers to the spliced, processed form of the XBP-1 mRNA or the corresponding protein. Spliced forms of XBP-1 are key factors in the transcriptional regulation of molecular chaperones and enhance compensatory UPR. Activation of UPR leads to activation of 1-1 which has an endoribonuclease activity which generates the active (i.e., spliced) form of XBP-1. Spliced XBP-1 is involved in the transcription of ER chaperones and components of the ER associated degradation (ERAD) pathway.
• ERP ER associated degradation
• a 26 nt intron is excised upon splicing of XBP-1 resulting in an increase in mobility of the mRNA when subject to electrophoresis.
• Spliced XBP-1 products can be detected by rtPCR, preferably quantitative rtPCR, using primers flanking the splice site for the PCR.
• the design of primers to detect relative quantities of unspliced and spliced mRNAs is well known to those skilled in the art.
• this splicing event results in the conversion of a 267 amino acid unspliced XBP-1 protein to a 371 amino acid spliced XBP-1 protein due to a frameshift in the coding sequence.
• the spliced XBP-1 then translocates into the nucleus where it binds to its target sequences to induce the transcription of molecular chaperones and other components of the UPR.
• An increase in the amount of spliced XBP-1 is preferably determined by an increase in the level of spliced XBP-1 as compared to the level of unspliced XBP-1.
• Unspliced XBP-1 is a negative regulator of the transcription of XBP-1.
• Subject refers to living organisms. In certain embodiments, the living organism is an animal. In certain preferred embodiments, the subject is a mammal. In certain embodiments, the subject is a domesticated mammal. In certain embodiments, the subject is a human. Examples of subjects include humans, monkeys, dogs, cats, mice, rats, cows, horses, goats, and sheep. The subject may be diagnosed with tuberous sclerosis. In other embodiments, the subject has been diagnosed with some other hamartomatous disease.
• Treat means to care for or deal with medically, or to act upon with some agent especially to improve or alter a condition or disease state such as tuberous sclerosis or other hamartomatous disease with an effective amount of an ER stress modulating agent. Treatment need not be curative. More than one dose of an agent that modulates ER stress may be required for the treatment of disease.
• Tuberous sclerosis refers to the complex of signs and symptoms associated with tuberous sclerosis complex.
• the signs and symptoms are a result of defects in the genes TSC1 or TSC2.
• Tuberous sclerosis can lead to tumors in any organ of the body including kidneys, heart, eyes, lungs, pancreas, liver, and skin. The disease may also lead to cysts such as bone cysts or kidney cysts. Tuberous sclerosis is frequently associated with neurological problems such as seizures and behaviors problems. Treatment of tuberous sclerosis refers to reducing any of these signs or symptoms including reducing tumor burden, reducing development of tumors, reducing number of tumors, reducing frequency or severity of seizures, reducing the number or frequency of skin lesions, improving renal function, etc.
• Endoplasmic reticulum (ER) stress has been found to be important in the pathogenesis of a variety of diseases including od-anti-trypsin deficiency, urea cycle disorders, type I and type II diabetes, obesity, insulin resistance, and cystic fibrosis.
• the present invention stems from the recognition that ER stress is implicated in the pathogenesis of tuberous sclerosis and other hamartomatous diseases.
• cells deficient in either TSC1 or TSC2 have been shown to have increased PERK and S6K1 phosphorylation, increased spliced XBP-1 levels, and increased GRP78/BIP and CHOP mRNA levels as compared to wild type cells in response to glucose starvation.
• the increase in these markers of ER stress was blocked by rapamycin which inhibits signaling through the mTOR pathway, one of the major sensors of nutrients and energy balance in the cells.
• PERK phosphorylation was also blocked by treatment of the cells with cyclohexamide. Cyclohexamide inhibits protein synthesis, thereby decreasing ER load, which in turn decreases ER stress in response to glucose starvation.
• hemangiomas from liver and cystic adenomas from kidney of TSC2+/ ⁇ mice exhibit signs of ER stress, particularly, increased IRE-1, PERK, and eIF2- ⁇ phosphorylation in liver hemangiomas, and increased GRP78/BIP expression in renal adenomatas tissue, but not in the adjacent normal tissue.
• Similar increases in ER stress markers, including increased eiF2 ⁇ and increased expression of GRB78/BIP protein were observed in a study using human tuber dissected in an epilepsy surgery. An increase in S6 phosphorylation, indicating the hyperactivity of the mTOR pathway was observed. Therefore, tissue samples from mouse and human tumors confirm the observations made in MEF regarding ER stress in TSC-deficient cells.
• TSC1 or TSC2 function leads to severe inhibition of insulin/IGF-1 stimulated insulin responsive substrate (IRS)-1 and -2 tyrosine phosphorylation, and distally Akt phosphorylation. Moreover, UPR leads to an inhibition of insulin receptor signaling.
• IGF-1 stimulated insulin responsive substrate (IRS)-1 and -2 tyrosine phosphorylation and distally Akt phosphorylation.
• UPR leads to an inhibition of insulin receptor signaling.
• Treatment of both TSC1- and TSC2-deficient cells with PBA resulted in a correction of insulin signaling as demonstrated by phosphorylation of IRS-1, IRS-2, and Akt in response to insulin stimulation.
• ER stress was shown to promote degradation of IRS-1.
• Cells were treated with ER stress inducers thapsigargin or tunicamycin in the presence of a proteosome inhibitor, either epoxomicin or MG132.
• IRS-1 was found to be extensively ubiquitinated and targeted for protein degradation. Ubiquitination could be blocked by preincubation of the cells with a JNK inhibitor.
• TSC-deficient cells were also found to be sensitive to ER stress inducers (i.e., thapsigargin or tunicamycin) as exhibited by increased production of spliced XBP-1 and cell death at low concentrations of ER stress inducers that had no effect on wild type cells at the same concentration.
• ER stress inducers i.e., thapsigargin or tunicamycin
• TSC2-deficient cells were at least partially rescued from ER stress inducer sensitivity by transfection with a retroviral expression vector encoding TSC2, or by treatment with the chemical chaperone PBA.
• ER stress inducing agents were administered to heterozygous TSC2+/ ⁇ mice with both kidney adenomas and liver hemangiomas. An apoptosis was observed in the tumors of the mice. Therefore, TSC-deficient cells such as those found in tumors of subjects suffering from tuberous sclerosis can be selectively killed by ER stress inducing agents. No overt toxicity was observed in normal tissue.
• the present invention includes the use of agents that modulate ER stress in the treatment of tuberous sclerosis.
• Any agent known to reduce or modulate ER stress can be useful in treating tuberous sclerosis.
• these agents act to reduce or prevent ER stress.
• the agent may increase the capacity of the ER to process proteins (e.g., increasing the expression of ER chaperones, increasing the levels of post-translational processing machinery).
• the agent may reduce the quantity of proteins to be processed by the ER (e.g., decreasing the total level of protein produced in a cell, reducing the level of protein processed by the ER, reducing the level of mutant proteins, reducing the level of misfolded proteins). Yet other agents may cause the release of misfolded/mutant proteins from the ER.
• the agent may work in all cells, or the effect may be limited to certain cells type (e.g., secretory cells, epithelial cells, hepatocytes, adipocytes, endocrine cells, etc.).
• the agents are particularly useful in reducing ER stress in the cells of tuberous sclerosis tumors (e.g., tumors formed due to a TSC-deficiency regardless of the tissue affected). In other embodiments, the agents are useful in reducing ER stress in TSC-deficient cells. In other embodiments, agents to induce ER stress may be administered initially to reduce or eliminate the tumor burden, either alone or in conjunction with surgery. Upon elimination of the tumor(s), agents to decrease ER stress (e.g., chemical chaperones) can be administered to prevent recurrence of tumors. The agents may work on the transcriptional, translational, post-translational, or protein level to reduce or prevent ER stress.
• agents to induce ER stress may be administered initially to reduce or eliminate the tumor burden, either alone or in conjunction with surgery.
• agents to decrease ER stress e.g., chemical chaperones
• the agents may work on the transcriptional, translational, post-translational, or protein level to reduce or prevent ER stress.
• an effective dose of an ER stress modulator, or a combination therapy including an ER stress modulator, to a subject to alleviate, prevent, and/or treat tuberous sclerosis can reduce at least one sign or symptom of the disease, reduce the consequences of the disease, reduce the development of tuberous sclerosis-associated tumors, or provide some other transient beneficial effect to the subject.
• the invention includes the use of such agents for the preparation of a medicament for the alleviation, prevention, and/or treatment of tuberous sclerosis or other hamartomatous diseases.
• the inventive treatments and medicaments reduce levels of ER stress markers in cells (e.g., adipocytes, hepatocytes) or tuberous sclerosis tumors.
• ER stress modulating agents act to increase ER stress resulting in the death of TSC-deficient cells.
• agents that induce ER stress include, but are not limited to, thapsigargin, tunicamycin, and azetidine-2 carboxylic acid (Azc). These agents are particularly useful in controlling the tumors associated with tuberous sclerosis.
• the invention includes the use of such agents for the preparation of a medicament for the alleviation, prevention, and/or treatment of tuberous sclerosis or other hamartomatous diseases. As shown in herein, the tumors associated with tuberous sclerosis are deficient in TSC and are therefore sensitive to ER stress induced death.
• the present invention provides a medicament and a method for controlling tumors of tuberous sclerosis by administering a therapeutically effective amount of an ER stress inducing agent to a subject.
• the ER stress modulating agent is a small molecule.
• Particularly useful agents are known as chemical chaperones, which are known to stabilize proteins against denaturation and/or promote proper folding of both wild type and mutant proteins thereby preserving the protein's structure and function.
• the agent may be any type of chemical compound.
• the agent may be a small molecule, organometallic complex, an inorganic compound, a protein, a glycoprotein, a peptide, a carbohydrate, a lipid, or a nucleic acid.
• Chemical chaperones include glycerol, D 2 O, dimethylsulfoxide (DMSO), 4-phenyl butyrate (PBA), tauroursodeoxycholic acid (TUDCA), ursodeoxycholic acid (UDCA), glycine betaine (betaine), glycerolphosphocholine (GPC), methylamines, and trimethylamine N-oxide (TMAO).
• DMSO dimethylsulfoxide
• PBA 4-phenyl butyrate
• TDCA tauroursodeoxycholic acid
• UDCA ursodeoxycholic acid
• GPC glycine betaine
• GPC glycerolphosphocholine
• TMAO trimethylamine N-oxide
• combinations of one or more chemical chaperones may be used.
• These chemical chaperones are administered in doses ranging from 10 mg/kg/day to 10 g/kg/day, preferably 100 mg/kg/day to 5 g/kg/day, more preferably
• the agent to modulate ER stress may be combined with one or more other pharmaceutical agents, particularly agents traditionally used in the treatment of tuberous sclerosis to form a pharmaceutical composition or a medicament.
• agents useful in combination with ER stress reducing agents include, but are not limited to, antineoplastic agents, anti-epileptic agents, vitamins, and minerals.
• the ER stress modulator is used in combination with rapamycin.
• PBA is combined with rapamycin.
• a chemical chaperone or ER stress modulator e.g., PBA, TUDCA, UDCA, TMAO, or derivatives thereof
• a vitamin, mineral, or other nutritional supplement is used in combination with a vitamin, mineral, or other nutritional supplement.
• the ER stress modulator (e.g., PBA, TUDCA, UDCA, TMAO, or derivatives thereof) is administered in a sub-clinical dose (e.g., an amount that does not manifest detectable therapeutic benefits when administered in the absence of a second agent).
• a sub-clinical dose e.g., an amount that does not manifest detectable therapeutic benefits when administered in the absence of a second agent.
• the administration of such a sub-clinical dose of the ER stress modulator in combination with another agent results in at least an additive, preferably a synergistic effect.
• the ER stress modulator and other agent work together to produce a therapeutic benefit.
• the other agent i.e., not the ER stress modulator
• the combination exhibits a therapeutic effect.
• both the ER stress modulator and the other agent are each administered in sub-clinical doses, and when combined the agents produce a therapeutic effect.
• the dosages, route of administration, formulation, etc. for anti-neoplastic agents, anti-epileptic agents, vitamins, and minerals are known in the art.
• the treating physician or health care professional may consult such references as the Physician's Desk Reference (59th Ed., 2005), or Mosby's Drug Consult and Inreracations (2005) for such information. It is understood that a treating physician would exercise his or her professional judgment to determine the dosage regimen for a particular patient.
• small molecule agents shown to reduce ER stress include 4-phenyl butyrate (PBA), tauroursodeoxycholic acid (TUDCA), ursodeoxycholic acid (UDCA), and trimethylamine N-oxide (TMAO).
• PBA is used currently to treat ⁇ 1-anti-trypsin deficiency, urea cycle disorders, and cystic fibrosis.
• UDCA is used to treat primary biliary cirrhosis.
• Derivatives, salts (e.g., sodium, magnesium, potassium, magnesium, ammonium, etc.), prodrugs, esters, isomers, and stereoisomers of PBA, TUDCA, or TMAO may also be used to treat obesity, hypergylcemia, type II diabetes, and insulin resistance. Without wishing to be bound by any particular theory, these compounds are thought to work by allowing the ER to better tolerate misfolded and/or mutant proteins being processed by the ER.
• a derivative of 4-phenyl butyrate useful in the present invention is of the formula:
• n 1 or 2;
• R 0 is aryl, heteroaryl, or phenoxy, wherein the aryl, heteroaryl, and phenoxy being unsubstituted or substituted with, independently, one or more halogen, hydroxy, or lower alkyl (C 1 -C 6 ) groups;
• R 1 and R 2 are independently H, lower alkoxy (C 1 -C 6 ), hydroxy, lower alkyl or halogen;
• R 3 and R 4 are independently H, lower alkyl, lower alkoxy or halogen; or
• R 0 is a substituted or unsubstituted phenyl ring. In certain embodiments, R 0 is an unsubstituted phenyl ring. In other embodiments, R 0 is a monosubstituted phenyl ring. In yet other embodiments, R 0 is a disubstituted phenyl ring. In still other embodiments, R 0 is a trisubstituted phenyl ring. In certain embodiments, R 0 is a phenyl ring substituted with 1, 2, 3, or 4 halogen atoms. In certain embodiments, R 0 is a substituted or unsubstituted heteroaryl ring.
• R 0 is a naphthyl ring. In certain embodiments, R 0 is five- or six-membered ring, preferably a six-membered ring. In certain embodiments, R 1 and R 2 are both hydrogen. In certain embodiments, n is 1. In other embodiments, n is 2. In certain embodiments, both R 3 and R 4 are hydrogen. In other embodiments, at least one of R 3 or R 4 is hydrogen. In certain embodiments, the compound is used in a salt form (e.g., sodium salt, potassium salt, magnesium salt, ammonium salt, etc.). Other derivatives useful in the present invention are described in U.S. Pat. No. 5,710,178, which is incorporated herein by reference. 4-phenyl butyrate or its derivatives may be obtained from commercial sources, or prepared by total synthesis or semi-synthesis.
• a salt form e.g., sodium salt, potassium salt, magnesium salt, ammonium salt, etc.
• a derivative of TUDCA useful in the present invention is of the formula:
• R is —H or C 1 -C 4 alkyl
• R 1 is —CH 2 —SO 3 R 3 and R 2 is —H; or R 1 is —COOH and R 2 is —CH 2 —CH 2 —CONH 2 , —CH 2 —CONH 2 , —CH 2 —Cl4 2 —SCH 3 or —CH 2 —S—CH 2 —COOH; and
• R 3 is —H or a basic amino acid; or a pharmaceutically acceptable salt thereof.
• the stereochemistry of the derivative is defined as shown in the following structure:
• R is H. In other embodiments, R is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, or tert-butyl, preferably, methyl.
• R 1 or R 2 is hydrogen. In certain embodiments, R 1 is —CH 2 —SO 3 R 3 and R 2 is —H. In other embodiments, R 1 is —COOH and R 2 is —CH 2 —CH 2 —CONH 2 , —CH 2 —CONH 2 , —CH 2 —CH 2 —SCFI 3 or —CH 2 —S—CH 2 —COOH. In certain embodiments, R 3 is hydrogen.
• R 3 is lysine, arginine, ornithine, or histidine.
• Derivatives of TUDCA and ursodeoxycholic acid (UDCA) may be obtained from commercial sources, prepared from total synthesis, or obtained from a semi-synthesis. In certain embodiments, the derivative is prepared via semi-synthesis, for example, as described in U.S. Pat. Nos. 5,550,421 and 4,865,765, each of which is incorporated herein by reference.
• derivative of trimethylamine N-oxide useful in the present invention is of the formula:
• R 1 R 2 , and R 3 are independently hydrogen, halogen, or lower C 1 -C 6 alkyl; or a pharmaceutically-acceptable salt thereof; or a mixture thereof.
• R 1 , R 2 , and R 3 are the same.
• at least one of R 1 , R 2 , and R 3 is different.
• all of R 1 , R 2 , and R 3 are different.
• R 1 , R 2 , and R 3 are independently hydrogen or lower C 1 -C 6 alkyl.
• R 1 , R 2 , and R 3 are independently lower C 1 -C 6 alkyl.
• R 1 , R 2 , and R 3 are independently methyl, ethyl, or propyl. In certain embodiments, R 1 , R 2 , and R 3 are ethyl. Derivatives of TMAO may be obtained from commercial sources, or prepared by total synthesis or semi-synthesis.
• a therapeutically effective amount of the agent is administered to the subject via any route to achieve the desired biological result.
• Any route of administration may be used including oral, parenteral, intravenous, intraarterial, intramuscular, subcutaneous, rectal, vaginal, transdermal, intraperitoneal, and intrathecal.
• the agent is administered parenterally. In other embodiments, the agent is administered orally.
• the agent is preferably administered orally; however, any of the administration routes listed above may also be used.
• the PBA, TUDCA, UDCA or TMAO is administered parenterally, PBA is administered in doses ranging from 10 mg/kg/day to 5 g/kg/day, preferably from 100 mg/kg/day to 1 g/kg/day, more preferably from 250 mg/kg/day to 750 mg/kg/day.
• TUDCA is administered in doses ranging from 10 mg/kg/day to 5 g/kg/day, preferably from 100 mg/kg/day to 1 g/kg/day, more preferably from 250 mg/kg/day to 750 mg/kg/day.
• TMAO is administered in doses ranging from 0.1 g/kg/day to 10 g/kg/day, preferably from 0.5 g/kg/day to 5 g/kg/day, more preferably from 500 mg/kg/day to 2.5 g/kg/day.
• the agent is administered in divided doses (e.g., twice per day, three times a day, four times a day, five times a day). In other embodiments, the agent is administered in a single dose per day.
• compositions and medicaments of the present invention may include a pharmaceutically acceptable excipient or carrier.
• pharmaceutically acceptable carrier means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material, or formulation auxiliary of any type.
• materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil; and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; detergents such as Tween 80; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; artificial cerebral spinal fluid (CSF), and phosphate buffer solutions, as well as
• sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
• the sterile injectable preparation may also be a sterile injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
• acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P., and isotonic sodium chloride solution.
• sterile, fixed oils are conventionally employed as a solvent or suspending medium.
• any bland fixed oil can be employed including synthetic mono- or diglycerides.
• fatty acids such as oleic acid are used in the preparation of injectables.
• the injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
• the pharmaceutical compositions of the invention may be provided in a kit with other agents used to treat tuberous sclerosis or other hamartomatous disease.
• the kit may include instructions for the treating physician and/or patient, which may include dosing information, safety information, list of side effects, chemical formula of agent, mechanism of action, etc.
• the kit may include materials for administering the pharmaceutical composition.
• the kit may include a syringe, needle, alcohol swabs, etc. for the administration of an injectable preparation.
• the active pharmaceutical ingredients may be formulated separately or together.
• the kit may include a first container with as ER stress modulator (e.g., PBA, TUDCA, UDCA, TMAO, or a derivative thereof) and a second container with a second agent used in treating tuberous sclerosis (e.g., anti-neoplastic agents, anti-epileptic agents, vitamins, and minerals, as described above).
• ER stress modulator e.g., PBA, TUDCA, UDCA, TMAO, or a derivative thereof
• a second agent used in treating tuberous sclerosis e.g., anti-neoplastic agents, anti-epileptic agents, vitamins, and minerals, as described above.
• the active pharmaceutical ingredients are formulated separately.
• the active pharmaceutical ingredients are formulated together.
• ER stress has been identified as a target for the treatment of tuberous sclerosis and other hamartomatous diseases. Markers of ER stress may be used as indicators of the disease or indicators of the effectiveness of treatment.
• a method of identifying agents useful in the treatment of tuberous sclerosis is needed.
• TSC-deficient cells are useful in a system for identifying agents as ER stress modulators.
• TSC1- and TSC2-deficient cells represent a cell model of spontaneous ER stress and provide a useful platform to investigate ER stress in the cell. These TSC-deficient cells are useful in screening for ER stress modulators without the use of compounds or drugs that modify ER function.
• Kits can further include control agents known to increase (e.g., ER stress inducers) or decrease ER stress (e.g., chemical chaperones), tissue culture reagents such as glucose-free media.
• the kit may include primers, hybridization probes, polynucleotides, antibodies, antibody fragments, gels, buffers, enzyme substrates, ATP or other nucleotides, tools for obtaining cells or a biopsy from the subject, instructions, software, etc. These materials for performing the diagnostic method may be conveniently packaged for use by a physician, scientist, or other individual skilled in the art.
• a test compound or a collection of test compounds is assayed using TSC-deficient cells or whole animals (e.g., heterozygous TSC1 ⁇ /+ or TSC2 ⁇ /+animals, or mosaic homozygous TSC1 ⁇ / ⁇ or TSC2 ⁇ / ⁇ animals) to identify compounds that reduce or modulate ER stress in vivo or in vitro, preferably in vivo.
• TSC-deficient cells or whole animals e.g., heterozygous TSC1 ⁇ /+ or TSC2 ⁇ /+animals, or mosaic homozygous TSC1 ⁇ / ⁇ or TSC2 ⁇ / ⁇ animals
• These test compounds may be any type of chemical compound including small molecules, proteins, peptides, polynucleotides, carbohydrates, lipids, natural products, etc.
• a collection of compounds is screened using a method of the invention.
• a collection of compounds is screened using a high throughput screening method.
• test compounds can undergo preliminary screenings in one or more in vitro assays to identify compounds that modulate at least one marker of ER stress.
• the compounds can then be tested in appropriate animal models, such as the TSC-deficient heterozygous mice, using routine methods to determine if the test compound is also effective in vivo.
• appropriate animal models such as the TSC-deficient heterozygous mice
• Such methods of identification of compounds in vitro for further analysis in vivo is frequently employed in drug identification screening methods.
• test compound includes any agent that is employed in the inventive screening system and assayed for its ability to modulate (i.e., increase or decrease) ER stress. More than one compound, e.g., a plurality of compounds, can be tested at the same time for their ability to modulate ER stress in the inventive system. Preferably, the subject assays identify compounds not previously known to have the effect on ER stress, although the compound may be well known. In one embodiment, high throughput screening techniques and apparatuses can be used to identify compounds that modulate ER stress. Many methods of high throughput screening are well known to those skilled in the art. The exact method of screening test compounds is not a limitation of the instant invention.
• the compounds to be tested can be derived from libraries (i.e., are members of a library of compounds). These collections may be historical libraries of compounds from pharmaceutical or biotech companies. In certain embodiments, the collection may be a combinatorial library of chemical compounds. The collection may include at least about 5, 10, 50, 100, 500, 1000, 10000, 100000, or 1000000 compounds. While the use of libraries of peptides is well established in the art, new techniques have been developed which have allowed the production of mixtures of other compounds, such as benzodiazepines (Bunin et al. (1992). J. Am. Chem. Soc. 114:10987; DeWitt et al. (1993). Proc. Natl. Acad. Sci.
• the compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries, spatially addressable parallel solid phase or solution phase libraries, synthetic library methods requiring deconvolution, the “one-bead one-compound” library method, and synthetic library methods using affinity chromatography selection.
• the biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer, or small molecule libraries of compounds (Lam (1997) Anticancer Drug Des. 12:145; incorporated herein by reference).
• Other exemplary methods for the synthesis of molecular libraries can be found in the art, for example in: Erb et al., (1994). Proc. Natl. Acad. Sci. USA 91:11422; Horwell et al. (1996) Immunopharmacology 33:68; and in Gallop et al. (1994); J. Med. Chem. 37:1233; each of which is incorporated herein by reference.
• the combinatorial polypeptides are produced from a cDNA library.
• TSC-deficient cells are contacted with a test compound.
• the cells are deficient in TSC1.
• the cells are TSC1 ⁇ / ⁇ .
• the cells are TSC1 ⁇ /+.
• the cells are deficient in TSC2.
• the cells are TSC2 ⁇ / ⁇ .
• the cells are TSC2 ⁇ /+.
• the TSC-deficiency in the cells may be the result of genetic engineering of the cells or animals.
• the cells may be from a naturally occurring TSC-deficient cells from a cell line or tumor.
• the cells are preferably animal cells.
• mammalian cells are preferred, human cells.
• the cells may be derived from any organ system.
• cells are derived from tuberous sclerosis-associated tumors.
• the TSC-deficient cells are contacted with a test compound(s).
• cells stimulated with an agent to induce ER stress prior to contact with the compound are contacted with a test compound(s).
• the level of ER stress markers may be assayed before and/or after addition of the test compound to determine if the compound modulates ER stress.
• a control is preferably used where no test compound is added to the cells. Time course assays can be used to further analyze test compounds.
• a positive control agent known to reduce ER stress e.g., PBA
• that inhibits signaling through the mTOR pathway e.g., rapamycin
• An additional control may also be used in the assay where an agent known to induce ER stress (e.g., thapsigargin, tunicamycin, azetidine-2 carboxylic acid) is added to the cell.
• ER stress e.g., thapsigargin, tunicamycin, azetidine-2 carboxylic acid
• one ER marker is measured.
• the levels of a combination of two, three, four, five, six, or more ER stress markers are measured.
• Test compounds that reduce the levels of ER stress markers by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%, preferably at least about 25%, more preferably at least about 50%, are considered useful for evaluation as ER stress reducers in further in vitro and in vivo testing.
• Test compounds that increase the levels of ER stress markers by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%, preferably at least about 25%, more preferably at least about 50%, are considered useful for evaluation of ER stress inducer in further in vitro and in vivo testing.
• the test compound may be tested at various concentrations and under various conditions (e.g., various cell types, various degrees of ER stress in the cell, various formulations, combined with other ER stress modulators).
• the invention provides for a method of identifying compounds that prevent ER stress.
• the cells are not experiencing ER stress before they are contacted with the test compound.
• an agent known to cause ER stress is added to the cells, and then the level of at least one ER markers is measured to determine whether the compound is able to prevent ER stress.
• the test compound may be tested at various concentrations for various times and under various conditions and levels of ER stress markers. Test samples can be compared to appropriate control samples.
• the invention provides for a method of identifying compounds that induce ER stress.
• cells may or may not be experiencing ER stress prior to being contacted with the test compound.
• Cells not experiencing ER stress can be assayed for the presence of at least one marker of ER stress.
• Cells experiencing ER stress e.g., TSC-deficient cells
• Test compounds found to induce apoptosis can be retested in the presence of a compound that blocks mTOR signaling (e.g., rapamycin) to determine if apoptosis is due to increased ER stress.
• a compound that blocks mTOR signaling e.g., rapamycin
• TSC-deficient cells can be screened in parallel with cells not experiencing ER stress (i.e., wild type cells), preferably cells of the same type (e.g., both fibroblast cell lines).
• ER stress i.e., wild type cells
• cells of the same type e.g., both fibroblast cell lines.
• Compounds that induce apoptosis in TSC-deficient cells, but not the wild type cells are likely inducing apoptosis by increasing ER stress.
• Agents identified by the methods of the invention may be further tested for toxicity, pharmacokinetic properties, use in vivo, etc. so that they may be formulated and used in the clinic to treat tuberous sclerosis.
• the identified agents may also find use in the treatment of other diseases associated with ER stress.
• Tuberous sclerosis has been demonstrated herein to be associated with ER stress. Therefore, measuring the level of an ER stress marker(s) in a subject, preferably in effected tissue, allows for determining whether a patient has tuberous sclerosis. Determining the level of an ER stress marker may also be used to follow the progression of a patient's tuberous sclerosis or to follow the effectiveness of the treatment of a patient's disease. Tissue can be obtained by biopsy, surgical resection, or other methods well known to those skilled in the art.
• ER stress markers and methods for measuring them have been identified and are discussed herein. These ER stress markers may be measured using any techniques known in the art for measuring mRNA levels, protein levels, protein activity, or phosphorylation status. Exemplary techniques for measuring ER stress markers include western blot analysis, ELISA, northern blot analysis, immunoassays, quantitative PCR analysis, and enzyme activity assay (for a more detailed description of these techniques, please see Ausubel et al. Current Protocols in Molecular Biology (John Wiley & Sons, Inc., New York, 1999); Molecular Cloning: A Laboratory Manual, 2nd Ed., ed. by Sambrook, Fritsch, and Maniatis (Cold Spring Harbor Laboratory Press: 1989); each of which is incorporated herein by reference).
• the levels of ER stress markers may be determined from any cells in the subject's body. In certain embodiments, the cells are cells from a tuberous sclerosis associated tumor. The cells may be obtained in any manner including biopsy or surgical excision.
• kits and systems for measuring the levels of various ER stress markers in a subject with tuberous sclerosis may include primers, hybridization probes, polynucleotides, antibodies, antibody fragments, gels, buffers, enzyme substrates, ATP or other nucleotides, tools for obtaining cells or a biopsy from the subject, instructions, software, etc.
• These materials for performing the diagnostic method may be conveniently packaged for use by a physician, scientist, pathologist, nurse, lab technician, or other health care professional.
• hamatomatous diseases Besides tuberous sclerosis, there are other hamatomatous diseases. These disease may also be associated with ER stress, and therefore be susceptible to treatment with ER stress modulators.
• Other hamartomatous diseases include pulmonary hamartoma, von Meyenburg complex, proteus syndrome, Birt-Hogg-Dube syndrome, multiple hamartoma syndrome, neurofibromatosis type I, Peutz-Jeghers syndrome, Riley-Smith syndrome, and angiomyolipoma.
• the disease are treated with ER stress reducers described herein. ER stress markers may be used to monitor the progression of the disease or the effectiveness of treatment.
• Anti-IRS-1 and anti-IRS-2 antibodies were obtained from Upstate Biotechnology (Charlottesville, Va.). Antibodies against phosphotyrosine, eIF2 ⁇ , JNK-1, and insulin receptor ⁇ subunit were from Santa Cruz Biotechnology (Santa Cruz, Calif.). Anti-phospho S6K, anti-S6K1, anti-phospho-PERK, antiphospho-eIF2 ⁇ , anti-Akt and anti-phospho-Akt antibodies, and c-Jun recombinant protein were from Cell Signaling Technology (Beverly, Mass.). Fluorescein-conjugated (FITC-conjugated) goat anti-rabbit IgG were from Jackson Immuno Research Laboratories (West Grove, Pa.).
• Thapsigargin was from Calbiochem (San Diego, Calif.). Cell Death Elisa Kit and BM Chemiluminescence Blotting Substrate (POD) were from Roche (Indianapolis, Ind.). The antiphospho-IRE-1 antibody was a gift from Dr. Fumihiko Urano from University of Massachusetts
• mice embryonic fibroblast (MEF) cell lines (TSC1+/+, TSC1 ⁇ / ⁇ , TSC2+/+, TSC2 ⁇ / ⁇ ) were cultured in medium containing DMEM-H+10% fetal bovine serum (FBS)+1% PS (penicillin-streptomycin complex) in 175 cm 2 cell culture flasks using standard methods. Upon reaching 90% confluency, cells were split into 10 cm dishes at 30-40% confluency and grown again in DMEM-H+10% FBS+1% PS to about 60% confluency for experiments.
• FBS fetal bovine serum
• PS penicillin-streptomycin complex
• Protein extracts were prepared with a lysis buffer containing 25 mM Tris-HCl (pH 7.4), 2 mM Na 3 VO 4 , 10 mM NaF, 10 mM Na 4 P 2 O 7 , 1 mM EGTA, 1 mM EDTA, 1% NP-40, 5 ug/ml leupeptin, 5 ug/ml aprotinin, 10 nM okadaic acid, and 1 mM phenylmethylsulfonyl fluoride (PMSF). Immunoprecipitations and immunoblotting experiments were performed with 200 and 75 ⁇ g total protein, respectively without any freeze-thaw cycles from individual aliquots.
• PMSF phenylmethylsulfonyl fluoride
• Protein concentrations were normalized and the desired amounts were aliquotted into tubes.
• Laemelli buffer was added to a 1 ⁇ final concentration and the samples were boiled for five minutes. After boiling, the samples were incubated at room temperature for 20 minutes. The boiled, cooled lysates were centrifuged at 14,000 rpm and subject to SDS-PAGE. Proteins were transferred to PVDF membranes for western blotting.
• Membrane blotting was performed using standard techniques and reagents. Appropriate modification depending on the antibodies used and other considerations, is within the ability of those skilled in the art.
• Membranes were blocked in 10% blocking reagent for 1 hour prior to exposure to primary antibody in tris-buffered saline-tween (TBST), pH 7.4, overnight at 4° C. Following overnight incubation, membranes were washed in TBST for 3 ⁇ 20 minutes and placed into secondary antibody for 1 hour. Subsequently the membrane was washed 3 ⁇ 20 minutes in TBST. After the washing period, the membranes were developed by using a chemiluminescence kit and the bands were visualized using a phospho imager system (VersaDoc Imaging System, Model 3000).
• Cell lysates were prepared as above, and subsequently incubated with primary antibody and Sepharose beads, either Protein A Sepharose or Protein G Sepharose depending on the antibody. The samples were incubated on a rotating apparatus overnight at 4° C. Subsequently, beads were centrifuged at 14,000 rpm and washed 3 times with cold lysis buffer. If immunoprecipitates were to be subjected to SDS-PAGE, they were boiled in 2 ⁇ Laemmli buffer for 5 minutes prior to loading.
• JNK c-Jun Amino Terminal Kinase
• the beads were washed 3 times with lysis buffer as described above, and two times with JNK kinase assay buffer (25 mM HEPES (pH: 7.4), 20 mM MgCl 2 , 20 mM ⁇ -glycerophosphate, 0.5 mM EGTA, 0.5 mM NaF, 0.5 mM NaOrthoVanadate, 1 mM PMSF) for equilibration. After washing with kinase buffer, the beads were incubated in 17 ⁇ l kinase buffer, 1 ⁇ l [ 32 P] ⁇ -ATP and 4 ⁇ g of c-Jun fusion protein at 30° C. for 20 minutes. The reaction was terminated by the addition of Laemmli buffer. The samples were resolved by SDS-page and transferred to a PVDF membrane as described above. Phosphorylated c-Jun bands were visualized prior to western blotting.
• JNK kinase assay buffer 25 mM HEPES
• TSC2- and TSC1-Deficient Cells have Increased Levels of Er Stress Markers
• ER stress markers PERK and s6K1 were analyzed in both wild type (TSC2+/+ and TSC1+/+) and TSC-deficient (TSC2 ⁇ / ⁇ and TSC1 ⁇ / ⁇ ) MEFs.
• Cells were cultured and treated with DMSO (vehicle control) or rapamycin as discussed above. Rapamycin inhibits signaling through the mTOR pathway which is required for ER stress response.
• the DMSO was present at too low of a concentration to act as a chemical chaperone.
• Cells were harvested and protein and RNA were isolated. Protein samples were resolved by SDS-PAGE and proteins were transferred to PVDF membrane for western blotting as described above.
• RNA was subjected to rt-PCR using probes designed to mouse XBP-1 to detect splicing.
• the western blot was probed with antibodies targeted to phosphorylated (i.e., activated) ER stress markers PERK, s6K1, and ribosomal protein S6, and to total s6K1 as a control for protein loading.
• the levels of unspliced (XBP-1(u)) and spliced (XBP-1(s)) mRNA were also analyzed, as were the levels of GRP78/BIP and CHOP.
• TSC1 or TSC2 demonstrated increased PERK, s6K1, and ribosomal protein S6 phosphorylation compared to wild type (TSC1+/+ and TSC2+/+) control cells, reflecting increased ER stress or unfolded protein response (UPR) in the absence of the TSC1 or TSC2 gene.
• An increase in p70 s6K1 kinase activity is known to occur with ER stress and was used here as a positive control.
• Incubation with rapamycin 200 nM, 12 hours), which blocks mTor activity, abolished the PERK, s6K1, and S6 phosphorylation and substantially reduced the presence of spliced XBP-1.
• TSC2 ⁇ / ⁇ cells The ER stress response to glucose starvation in TSC2 ⁇ / ⁇ cells is a result of the deletion of TSC2.
• An expression vector with (+TSC2) or without (+VEC) was transfected into the TSC2 ⁇ / ⁇ MEFs prior to serum starvation.
• Expression of TSC2 from the retroviral vector substantially decreased the ER stress response as shown by a decrease in the spliced XBP-1 product and decreased phosphorylation of PERK, S6K1, and S6.
• ER stress causes an increase in protein translation, at least partially due to induction of the UPR.
• MEFs undergoing ER stress were treated with cyclohexamide, a well known inhibitor of translation initiation. Cyclohexamide was found to decrease phosphorylation of PERK in both TSC1- and TSC2-deficient cells.
• ER stress due to loss of TSC1 or TSC2 can be inhibited by blocking signaling through the mTOR pathway.
• ER stress can also be attenuated by expression of TSC2 in TSC2 ⁇ / ⁇ cells.
• inhibition of protein synthesis also results in a decrease in the presence of ER stress markers in TSC-deficient cells.
• TSC2+/ ⁇ mice develop several tumors around 6-12 months due to a loss of heterozygosity (LOH). Frequently, giant hemangiomas develop in the liver and cystic adenomas develop in the kidney. Twelve month old TSC2+/ ⁇ mice on a C57BL/6j-129/SvJae mix background were euthanized according to approved protocols. Livers and kidneys were dissected and directly fixed in 10% buffered neutral formalin. Following fixation the tissues were paraffin embedded, and 5 micron sections were prepared for hematoxylin and eosin (H&E) histological staining and immunohistochemical analysis.
• H&E hematoxylin and eosin
• H&E staining was carried out using routine methods. Hematoxylin stains negatively charged nucleic acids (nuclei & ribosomes) blue, and eosin stains proteins pink to reveal cell morphology. Sections for immunofluorescence staining were washed 3 ⁇ 10 minutes in phosphate buffered saline (PBS), and incubated in 1% Triton X-100 in PBS for 10 minutes. Next, the samples were washed for 3 ⁇ 10 minutes in PBS, and incubated in 5% bovine serum albumin (BSA) in PBS for 1 hour.
• PBS phosphate buffered saline
• Tuberous Sclerosis Tumors from TSC-Deficient Mice Exhibit Increased ER Stress Markers
• mTOR pathway is activated in the tumors in TSC-2+/ ⁇ mice arising due to LOH.
• Immunofluorescent staining revealed that S6 phosphorylation in both liver and kidney tumors was increased, indicating signaling through the mTOR pathway.
• Analysis ER stress markers PERK, eIF2a, and IRE-1 phosphorylation showed a striking increase in the hemangiomas.
• GRP-78 protein levels were found to increase a significantly increase in kidney adenomas.
• Tuberous Sclerosis Tumors from Human Exhibit Increased ER Stress Markers
• Phosphorylation state of the ER stress markers PERK, eIF2 ⁇ cJun, JNK and s6K1, and the level of spliced XBP-1 were analyzed in both wild type and TSC-deficient MEFs.
• Cells were treated with PBS (vehicle control) or PBA (chemical chaperone) as discussed above. Cells were harvested, samples were resolved by SDS-PAGE, proteins were transferred to PVDF membrane, and western blots were performed as described above.
• PERK phosphorylation is upregulated in TSC2-deficient cells. An increase in S6K1 and eIF2 ⁇ phosphorylation was also observed. PBA treatment relieved ER stress and blocked PERK and eIF2 ⁇ phosphorylation. Phosphorylation of S6K1 was not blocked by PBA treatment. In addition, the c-Jun Amino Terminal Kinase-1 (JNK-1) activity was also suppressed by PBA treatment.
• TSC-1 and TSC-2 function were found lead to severe inhibition of insulin/IGF-1-stimulated IRS-1 and IRS-2 tyrosine phosphorylation, and distally Akt serine phosphorylation.
• UPR leads to inhibition of insulin receptor signaling
• the contribution of UPR to development of the negative feedback loop to insulin/IGF-1 signaling in TSC-1 ⁇ / ⁇ and TSC-2 ⁇ / ⁇ cells was investigated. Stimulation of TSC-1 ⁇ / ⁇ and TSC-2 ⁇ / ⁇ cells with insulin showed a slight or no increase in IRS-1 and -2 tyrosine and Akt serine phosphorylations.
• PBA treatment improved insulin induced IRS-1 and -2 tyrosine phosphorylation, and also Akt phosphorylation even in the conditions of severe S6K1 activation.
• IRS-1 Treatment with PBA, and consequently a decrease ER stress led to an increase in protein levels of IRS-1 and to a lesser extent IRS-2. Therefore, the possibility that ER stress leads to increased degradation of IRS-1 was investigated. It has been previously shown that when ER stress is induced acutely, IRS-1 is highly phosphorylated at serine 307 residue, and insulin induced tyrosine phosphorylation is blocked. However, prolonged exposure to ER stress created either by thapsigargin or tunicamycin treatment lead to degradation of IRS-1 as demonstrated herein. Stimulation of cells either tunicamycin or thapsigargin for 8 hours in the presence of a 26S proteosome inhibitor, epoxomicin, lead to severe ubiquitination of IRS-1.
• IRS-1 protein levels became totally undetectable in an hour after cycloheximide addition, whereas pretreatment with PBA extends this period up to 4 hours. Similar results were also obtained from TSC-2 ⁇ / ⁇ cells, which strongly indicates that ER stress plays an important role in enhanced degradation of IRS-1 in TSC deficiency and, over all, contributes to the development of negative feed back loop for insulin resistance.
• TSC-1-Deficient Cells have Increased Sensitivity to ER Stress Inducing Agents
• ER stress can cause apoptosis.
• the ability of ER stress inducers to promote apoptosis in TSC 1-deficient cells at concentrations that do not promote apoptosis in normal cells was analyzed. Wild-type and TSC1 ⁇ / ⁇ cells were plated in 96 well plates in DMEM-H+10% FBS+1% PS at 40-50% confluence. Upon reaching about 80% confluence, the cells were washed with DMEM-H without FBS and treated with the ER stress inducer thapsigargin (10 nM) or DMSO (vehicle control) for 6 hours in serum-free DMEM-H+1% PS. Apoptosis was analyzed by using Cell Death Elisa Kit using the manufacturer's instructions, or by detection of caspase 3 or PARP cleavage.
• TSC-deficient cells and their corresponding control cells were exposed to extremely low doses of thapsigargin (0.05 nM) and tunicamycin (0.002 ug/ml) at which the UPR is not activated in wild type control cells.
• TSC1- and TSC2-deficient cells responded to the ER stress inducers by activating the UPR as determined by increased splicing of XBP-1 mRNA when compared with their controls.
• TSC-deficient cells were then analyzed for apoptosis levels after thapsigargin and tunicamycin treatment.
• Induction of ER stress with thapsigargin in both TSC1 ⁇ / ⁇ and TSC2 ⁇ / ⁇ cells lead to massive apoptosis after 6 hours, whereas no apoptosis was observed in control cells during the same time period.
• Biochemical analysis of apoptosis indicators such as cleaved caspase-3 or PARP cleavage was significantly induced after thapsigargin treatment in TSC1 ⁇ / ⁇ cells when compared with their controls.
• Induction of ER stress also increased PARP and caspase-3 cleavage in TSC-2 ⁇ / ⁇ cells which could be blocked either by reconstitution of TSC-2 deficient cells by expression of TSC2 from a retroviral expression vector, or rapamycin treatment to inhibit mTOR signaling.
• TSC deficient cells The ability of TSC deficient cells to respond to glucose starvation in a similar way that they respond to ER stress inducing agents was investigated. Glucose starvation for 10 hours was not enough to induce XBP-1 splicing in wt cells; however, most of the XBP-1 mRNA were spliced in TSC-1 deficient cells after glucose starvation, indicating that TSC-1 deficient cells are much more sensitive to glucose starvation induced development of ER stress. The same is also true for TSC-2 deficient cells. The effect of 4-PBA on XBP-1 mRNA splicing after glucose starvation was analyzed.
• XBP-1 mRNA splicing was significantly reduced when the TSC-1/2 deficient cells are glucose starved in the presence of 4-PBA.
• CHOP expression was found to be up-regulated by ER stress and is an important element of ER stress induced apoptosis.
• Glucose starvation induced CHOP transcription was more than 10 fold (p ⁇ 0.001) in TSC-1 deficient cells when compared with their controls, and 4-PBA treatment significantly reduced glucose starvation induced CHOP transcription.
• PARP and caspase-3 cleavage after glucose starvation with or without 4-PBA in TSC1 and TSC2-deficient cells was also investigated.
• TSC-deficiency results in extreme sensitivity to glucose starvation induced apoptosis that originates from ER stress.
• thapsigargin Since the tumors arising due to LOH in TSC-2+/ ⁇ mice exhibit up-regulated UPR, we tested whether in vivo administration of thapsigargin will also selectively lead to apoptosis in the tumoral cells. To address this, we have used around ⁇ 1 year old TSC-2+/ ⁇ mice for thapsigargin (1 mg/kg) or vehicle treatment. After 7 days of thapsigargin administration we have analyzed the apoptosis with tunnel assay in the kidney adenomas. The tunnel assay positive cells showed a clear up-regulation in thapsigargin treated kidney adenomas.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Immunology (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Biomedical Technology (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Biotechnology (AREA)
• Cell Biology (AREA)
• Microbiology (AREA)
• Food Science & Technology (AREA)
• Biochemistry (AREA)
• Analytical Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Physics & Mathematics (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Publications (1)

Family

ID=38006516

Family Applications (2)

Family Applications After (1)

Country Status (3)

Cited By (8)

Families Citing this family (11)

Citations (6)

• 2006
  • 2006-11-01 US US12/092,345 patent/US20100022495A1/en not_active Abandoned
  • 2006-11-01 EP EP06836809A patent/EP1954254A4/fr not_active Withdrawn
  • 2006-11-01 WO PCT/US2006/042802 patent/WO2007053747A2/fr active Application Filing
• 2012
  • 2012-12-20 US US13/722,180 patent/US20140011761A1/en not_active Abandoned

Patent Citations (6)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events